Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Promissory Note On September 1, 2026, Profusa, Inc., a Delaware corporation (the “Company”), completed an additional closing under that certain Securities Purchase Agreement, dated as of February 11,
How this was made
The 30-second read
Why it matters
The financing provides short‑term liquidity with a conversion feature that may modestly dilute equity, but the small size limits market impact.
Market read
Primary disclosure of a micro‑cap financing event; low but concrete relevance for PFSA shareholders.
What to watch
Potential future conversion could increase share count if the stock price rises above $4.28.
Background
Profusa, a Nasdaq‑listed biotech, disclosed a senior secured convertible note issuance to Ascent Partners Fund.
Ticker impact
Profusa filed an 8‑K reporting issuance of a $300,000 senior secured convertible promissory note with 7% interest, convertible at $4.28 per share.
Minor upside if conversion terms are favorable; otherwise neutral.
Amount is trivial relative to market cap; conversion price above current share price limits upside.
Market effects
Limited effect on the broader biotech financing environment.
No significant regional impact.
Minimal global relevance.
Counterpoint
The note's terms could be viewed as favorable financing for a cash‑strapped micro‑cap, suggesting potential upside.
Key entities
- companyProfusa, Inc.
Issuer of the convertible note.
- investorAscent Partners Fund LLC
Purchaser and collateral agent for the note.